Atara Biotherapeutics Stock Today
| ATRA Stock | USD 12.18 0.08 0.65% |
Performance11 of 100
| Odds Of DistressOver 70
|
Atara Biotherapeutics is trading at 12.18 as of the 28th of November 2024, a 0.65 percent decrease since the beginning of the trading day. The stock's open price was 12.26. Atara Biotherapeutics has a very high chance of experiencing financial distress in the next few years of operation. However, it had a very good returns during the last 90 days. Equity ratings for Atara Biotherapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of August 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of October 2014 | Category Healthcare | Classification Health Care |
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company was incorporated in 2012 and is headquartered in South San Francisco, California. The company has 5.76 M outstanding shares of which 636.28 K shares are presently shorted by private and institutional investors with about 7.11 trading days to cover. More on Atara Biotherapeutics
Moving together with Atara Stock
| 0.77 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
Moving against Atara Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Atara Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Pascal DVM | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAtara Biotherapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Atara Biotherapeutics' financial leverage. It provides some insight into what part of Atara Biotherapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Atara Biotherapeutics (ATRA) is traded on NASDAQ Exchange in USA. It is located in 2380 Conejo Spectrum Street, Thousand Oaks, CA, United States, 91320 and employs 165 people. Atara Biotherapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 70.61 M. Atara Biotherapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 5.76 M outstanding shares of which 636.28 K shares are presently shorted by private and institutional investors with about 7.11 trading days to cover.
Atara Biotherapeutics currently holds about 331.31 M in cash with (192.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.51.
Check Atara Biotherapeutics Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Atara Biotherapeutics is $70.61 Million. Over half of Atara Biotherapeutics' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Atara Ownership Details
Atara Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Blackrock Inc | 2024-06-30 | 61.1 K | |
| Geode Capital Management, Llc | 2024-09-30 | 46.7 K | |
| Centiva Capital Lp | 2024-09-30 | 43.4 K | |
| Staley Capital Advisers Inc | 2024-09-30 | 40 K | |
| Bnp Paribas Arbitrage, Sa | 2024-06-30 | 36.7 K | |
| Fmr Inc | 2024-09-30 | 25.1 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 19.6 K | |
| Aqr Capital Management Llc | 2024-06-30 | 15.1 K | |
| State Street Corp | 2024-06-30 | 14.7 K | |
| Ecor1 Capital, Llc | 2024-09-30 | 468.9 K | |
| Redmile Group, Llc | 2024-09-30 | 452.3 K |
Atara Biotherapeutics Historical Income Statement
Atara Stock Against Markets
Atara Biotherapeutics Corporate Management
| Rajani MD | Senior Officer | Profile | |
| Eric Hyllengren | Executive Officer | Profile | |
| Jakob MD | Ex RD | Profile | |
| Kerry Daly | Head Communications | Profile | |
| Jill Henrich | Executive Quality | Profile | |
| Utpal MBA | Ex CFO | Profile | |
| Alex Chapman | Vice Relations | Profile |
Already Invested in Atara Biotherapeutics?
The danger of trading Atara Biotherapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Atara Biotherapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Atara Biotherapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Atara Biotherapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Atara Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Atara Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Atara Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Atara Biotherapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atara Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atara Biotherapeutics. If investors know Atara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atara Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (25.32) | Revenue Per Share 12.263 | Quarterly Revenue Growth 28.927 | Return On Assets (0.57) | Return On Equity (20.15) |
The market value of Atara Biotherapeutics is measured differently than its book value, which is the value of Atara that is recorded on the company's balance sheet. Investors also form their own opinion of Atara Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Atara Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atara Biotherapeutics' market value can be influenced by many factors that don't directly affect Atara Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atara Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Atara Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atara Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.